Table 3.
Validation of Final Multivariable Model for Grade 3-4 Acute Graft-Versus-Host Disease
Variable | RR | 95% CI | P |
---|---|---|---|
For recipients age 18-39 years | |||
Bone marrow graft | 1.0 | ||
Peripheral blood stem-cell graft | 1.51 | 1.07 to 2.14 | .0201 |
For recipients age 40+ years | |||
Bone marrow graft | 1.0 | ||
Peripheral blood stem-cell graft | 1.31 | 0.94 to 1.83 | .1091 |
Age for recipients of bone marrow transplants, years | |||
18-39 | 1.0 | ||
40+ | 1.43 | 1.04 to 1.96 | .0280 |
Age for recipients of peripheral-blood stem-cell transplants, years | |||
18-39 | 1.0 | ||
40+ | 1.24 | 0.86 to 1.79 | .2492 |
Race | |||
Asian/Hispanic | 1.0 | ||
White/Black | 1.03 | 0.75 to 1.41 | .8736 |
Leukemia type | |||
Acute myeloid or lymphoblastic leukemia | 1.0 | ||
Chronic myeloid leukemia | 1.32 | 1.03 to 1.69 | .0261 |
Karnofsky performance score at transplant | |||
90-100 | 1.0 | ||
0-80 | 1.47 | 1.12 to 1.93 | .0063 |
Conditioning regimen | |||
BuCy ± other | 1.0 | ||
CyTBI ± other | 0.99 | 0.77 to 1.27 | .9127 |
Recipient-donor cytomegalovirus status | |||
≥ 1 positive | 1.0 | ||
Both negative | 1.33 | 1.03 to 1.71 | .0308 |
Abbreviations: RR, relative risk; BuCy ± other, busulfan and cyclophosphamide with or without additional agents; CyTBI ± other, cyclophosphamide and total body irradiation with or without additional agents.